Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study.
Osamu YoshidaSheikh Mohammad Fazle AkbarYusuke ImaiTakahiro SanadaKyoko Tsukiyama-KoharaTakashi MiyazakiTaizou KamishitaTeruki MiyakeYoshio TokumotoHayato HikitaMasataka TsugeMasahito ShimizuMamun Al MahtabJulio Cesar AguilarGerardo GuillenMichinori KoharaYoichi HiasaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
Anti-HBs induction and HBsAg reduction was observed after CVP-NASVAC treatment in some patients with CHB. The CVP-NASVAC is a safe treatment, which might expect to achieve functional cure for patients with CHB.
Keyphrases